{"id":24874,"date":"2020-04-08T13:53:57","date_gmt":"2020-04-08T16:53:57","guid":{"rendered":"http:\/\/www.colfarma.info\/colfarma\/?p=24874"},"modified":"2023-06-28T10:04:10","modified_gmt":"2023-06-28T13:04:10","slug":"la-biblioteca-le-brinda-un-dossier-informativo-actualizado-sobre-coronavirus-covid-19","status":"publish","type":"post","link":"https:\/\/www.colfarma.info\/colfarma\/la-biblioteca-le-brinda-un-dossier-informativo-actualizado-sobre-coronavirus-covid-19\/","title":{"rendered":"La Biblioteca le brinda un dossier informativo actualizado sobre Coronavirus (COVID-19)"},"content":{"rendered":"

Sociedades cient\u00edficas: Recursos<\/strong><\/h2>\n

Resumen de recomendaciones vigentes para la Campa\u00f1a Nacional de Vacunaci\u00f3n contra la COVID-19
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2023-06\/actualizacion-lt-covid.pdf<\/a><\/p>\n

Dosis de refuerzo contra COVID-19 \u2013 Actualizaci\u00f3n
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2023-05\/memo-actualizacion-refuerzo-covid-19_03-5-2023.pdf<\/a><\/p>\n

Manual del vacunador de Pfizer Bivariante
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2023-01\/2023-01-manual-pfizer-bivariante.pdf<\/a><\/p>\n

OPS: ESAVI contra la COVID-19 y otras actualizaciones (abril 2023)
\nhttp:\/\/cime.fcq.unc.edu.ar\/wp-content\/uploads\/sites\/15\/2023\/05\/Actualizacio%C3%ACn-perio%C3%ACdica-ESAVI-vacunas-COVID-19-ABRIL-2023.pdf<\/a><\/p>\n

Monitor P\u00fablico de Vacunaci\u00f3n en tiempo real. Argentina
\nhttps:\/\/www.argentina.gob.ar\/coronavirus\/vacuna\/aplicadas<\/a><\/p>\n

Manual para Vacunadores Vacuna Sputnik Light
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2023-02\/manual-sputnik-light.pdf<\/a><\/p>\n

Manual para Vacunadores Vacuna SPIKEVAX BIVARIANTE, Original\/Omicron BA.4-5 (Vacuna COVID-19 ARNm, Moderna)
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2023-02\/manual-moderna-bivariante.pdf<\/a><\/p>\n

Memor\u00e1ndum | Refuerzos Vacunaci\u00f3n contra COVID-19 en ni\u00f1os, ni\u00f1as y adolescentes
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2023-01\/refuerzos-vacunacion-contra-COVID-19-en-ni%C3%B1os-ni%C3%B1as-adolescentes.pdf<\/a><\/p>\n

Memor\u00e1ndum | Uso de vacuna contra COVID-19 formulaci\u00f3n pedi\u00e1trica del laboratorio Moderna
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2023-01\/uso-de-vacuna-contra-COVID-19-formulacion-pediatrica-del-laboratorio-moderna.pdf<\/a><\/p>\n

Manual del vacunador de Pfizer Bivariante
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2023-01\/2023-01-manual-pfizer-bivariante.pdf<\/a><\/p>\n

Seguimiento de las variantes del SARS-CoV-2
\nhttps:\/\/www.who.int\/es\/activities\/tracking-SARS-CoV-2-variants\/tracking-SARS-CoV-2-variants<\/a><\/p>\n

An\u00e1lisis de la vacunaci\u00f3n contra la COVID-19 en la Regi\u00f3n de las Am\u00e9ricas. Desglose por sexo y edad y en subpoblaciones seleccionadas
\nhttps:\/\/iris.paho.org\/handle\/10665.2\/56734<\/a><\/p>\n

Programa de optimizaci\u00f3n del uso de antimicrobianos durante la pandemia de COVID-19
\nhttps:\/\/www.medicinabuenosaires.com\/revistas\/vol82-22\/n5\/641.pdf<\/a><\/p>\n

Salud recuerda la importancia de aplicar los refuerzos de vacuna contra COVID-19
\nhttps:\/\/www.argentina.gob.ar\/noticias\/salud-recuerda-la-importancia-de-aplicar-los-refuerzos-de-vacuna-contra-covid-19<\/a><\/p>\n

Memo: Tercer refuerzo en personas de 18 a\u00f1os o m\u00e1s
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2022-12\/Tercer%20refuerzo%20en%20personas%20de%2018%20a%C3%B1os%20o%20m%C3%A1s.pdf<\/a><\/p>\n

Frente a la suba de casos de COVID-19, Salud recomienda a la poblaci\u00f3n aplicarse los refuerzos de vacunas
\nhttps:\/\/www.argentina.gob.ar\/noticias\/frente-la-suba-de-casos-de-covid-19-salud-recomienda-la-poblacion-aplicarse-los-refuerzos<\/a><\/p>\n

19\u00b0 Informe de seguridad en vacunas
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2022-12\/informe-19-noviembre-2022.pdf<\/a><\/p>\n

Dudas generales sobre la vacunaci\u00f3n contra la COVID-19. Informaci\u00f3n para el paciente
\nhttps:\/\/iris.paho.org\/bitstream\/handle\/10665.2\/56512\/OPSFPLIMCOVID190032_spa.pdf?sequence=1&isAllowed=y<\/a><\/p>\n

Prevenci\u00f3n y Control de COVID-19 y otras Enfermedades Respiratorias Agudas en Residencias de Personas Mayores
\nhttps:\/\/portal-coronavirus.gba.gob.ar\/docs\/instituciones\/Recomendaciones-para-residencias-de-personas-mayores.pdf<\/a><\/p>\n

Vacunas de ARNm (Comirnaty y Spikevax) frente a la COVID-19 y riesgo de sangrado menstrual abundante
\nhttps:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2022\/docs\/NI_MUH_FV_07_2022-trastonos-menstruales.pdf<\/a><\/p>\n

EVUSHELD\u00ae: tixagevimab\/cilgavimab para el tratamiento de la COVID-19<\/p>\n

http:\/\/www.navarra.es\/NR\/rdonlyres\/6EAA15A8-75D9-4C43-B218-98D590FC247D\/483026\/FichaEvusheldTRATAMIENTO.pdf<\/a><\/p>\n

II Informe sobre el impacto de la pandemia por SARS-CoV-2 en las coberturas nacionales de vacunaci\u00f3n de Argentina
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2022-11\/II_informe_impacto_pandemia_sobre_coberturas_vacunacion.pdf<\/a><\/p>\n

Lineamientos T\u00e9cnicos | Tercer refuerzo
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2022-11\/lineamientos-tecnicos-tercer-refuerzo.pdf<\/a><\/p>\n

Reacciones adversas a medicamentos utilizados para la COVID-19 en cinco pa\u00edses de Am\u00e9rica Latina
\nhttps:\/\/iris.paho.org\/bitstream\/handle\/10665.2\/56484\/v46e1782022.pdf?sequence=1&isAllowed=y<\/a><\/p>\n

Posible impacto de la COVID-19 en el aumento de casos en Espa\u00f1a de enfermedad neumoc\u00f3cica por cepas resistentes a antibi\u00f3ticos
\nhttps:\/\/www.univadis.es\/viewarticle\/posible-impacto-de-la-covid-19-en-el-aumento-de-casos-en-espana-de-enfermedad-neumococica-por-cepas-resistentes-a-antibioticos-771372<\/a><\/p>\n

Comprueban que las mujeres vacunadas contra el COVID-19 transfieren protecci\u00f3n a sus hijos a trav\u00e9s de la leche materna, un hallazgo clave para los menores de 6 meses
\nhttps:\/\/www.agenciacyta.org.ar\/2022\/10\/comprueban-que-las-mujeres-vacunadas-contra-el-covid-19-transfieren-proteccion-a-sus-hijos-a-traves-de-la-leche-materna-un-hallazgo-clave-para-los-menores-de-6-meses\/<\/a><\/p>\n

Andaluc\u00eda: Preguntas frecuentes para Profesionales: Vacunaci\u00f3n frente a al COVID-19
\nhttps:\/\/www.andavac.es\/campanas\/covid\/informacion-para-profesionales\/preguntas-frecuentes\/<\/a><\/p>\n

COVID-19. Informe n\u00b0 80 julio 2022 OPS
\nhttps:\/\/iris.paho.org\/bitstream\/handle\/10665.2\/56298\/COVID-19SitRep80_spa.pdf?sequence=1&isAllowed=y<\/a><\/p>\n

Eventos adversos de inter\u00e9s especial y eventos adversos supuestamente atribuibles a la vacunaci\u00f3n o inmunizaci\u00f3n durante la introducci\u00f3n de las vacunas contra la COVID-19. Segunda edici\u00f3n
\nhttps:\/\/iris.paho.org\/handle\/10665.2\/56207<\/a><\/p>\n

Los pediatras de Atenci\u00f3n Primaria recomiendan tomar precauciones frente a virus respiratorios en la primera vuelta al cole sin medidas anti-covid. Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda (AEP)
\nhttps:\/\/www.aepap.org\/sites\/default\/files\/noticia\/archivos-adjuntos\/np_vuelta_al_cole_-_precauciones_virus.pdf<\/a><\/p>\n

Optimizaci\u00f3n de la vacunaci\u00f3n mediante la coadministraci\u00f3n de vacunas contra la gripe y el Covid-19: orientaci\u00f3n para farmac\u00e9uticos (FIP) (en ingl\u00e9s)
\nhttps:\/\/www.fip.org\/file\/5227<\/a><\/p>\n

Criterios para valorar la administraci\u00f3n de las nuevas alternativas terap\u00e9uticas antivirales frente a la infecci\u00f3n por SARS-CoV-2
\nhttps:\/\/www.aemps.gob.es\/medicamentos-de-uso-humano\/acceso-a-medicamentos-en-situaciones-especiales\/criterios-para-valorar-la-administracion-de-las-nuevas-alternativas-terapeuticas-<\/a><\/p>\n

Programa de optimizaci\u00f3n del uso de antimicrobianos durante la pandemia de covid-19
\nhttps:\/\/www.medicinabuenosaires.com\/revistas\/vol82-22\/destacado\/original_7779.pdf<\/a><\/p>\n

Seguridad y efectividad de vacuna COVID-19 SPUTNIK V en pacientes en di\u00e1lisis
\nhttp:\/\/www.nefrologiaargentina.org.ar\/numeros\/2022\/volumen20_1\/PremioMiatello.pdf<\/a><\/p>\n

ARGENVAC ser\u00e1 una herramienta para convivir con el virus de COVID-19
\nhttp:\/\/solp-admin.diper-it.com\/api\/uploads\/magazinearticles\/ARGENVAC-sera-una-herramienta-para-convivir-con-el-virus-de-COVID-19\/Preview_Revista_SOLP_62_Docena.pdf<\/a><\/p>\n

Vacunaci\u00f3n contra COVID-19 en ni\u00f1os y ni\u00f1as de 6 meses a 3 a\u00f1os y refuerzo de 3 y 4 a\u00f1os de edad. Sociedad Argentina de Pediatr\u00eda
\nhttps:\/\/www.sap.org.ar\/uploads\/documentos\/documentos_vacunacion-contra-covid-19-en-ninos-y-ninas-de-6-meses-a-3-anos-y-refuerzo-de-3-y-4-anos-de-edad-306.pdf<\/a><\/p>\n

Manual del Vacunador | Lineamientos T\u00e9cnicos Vacunaci\u00f3n con Moderna de 6 meses a 3 a\u00f1os y refuerzo de 3 y 4 a\u00f1os
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2022-07\/manual-vacunador-moderna-3-a-5-anos.pdf<\/a><\/p>\n

Actualizaciones basadas en evidencia COVID-19
\nhttps:\/\/www.argentina.gob.ar\/salud\/conetec\/actualizaciones<\/a><\/p>\n

COVID y rellenos faciales \u00bfrealmente debemos preocuparnos?
\nhttps:\/\/www.actasdermo.org\/es-pdf-S0001731022004689<\/a><\/p>\n

Preguntas frecuentes sobre la vacuna contra COVID-19
\nhttps:\/\/www.argentina.gob.ar\/coronavirus\/vacuna\/preguntas-frecuentes<\/a><\/p>\n

Glomerulonefritis por cambios m\u00ednimos post vacuna COVID-19 AstraZeneca
\nhttps:\/\/www.revistarenal.org.ar\/index.php\/rndt\/article\/view\/758\/1213<\/a><\/p>\n

Declaraci\u00f3n para los profesionales de la salud: c\u00f3mo se regulan las vacunas contra la COVID-19 para garantizar que son seguras y eficaces
\nhttps:\/\/www.who.int\/es\/news\/item\/11-06-2021-statement-for-healthcare-professionals-how-covid-19-vaccines-are-regulated-for-safety-and-effectiveness<\/a><\/p>\n

Lineamientos T\u00e9cnicos | Primer refuerzo en ni\u00f1os y ni\u00f1as de 5 a 11 a\u00f1os
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2022-05\/lineamientos-primer-refuerzo-personas-edad-5-11.pdf<\/a><\/p>\n

Evidencia sobre las vacunas para COVID-19 en ni\u00f1as, ni\u00f1os y adolescentes
\nhttps:\/\/www.evidencia.org\/index.php\/Evidencia\/article\/view\/6997\/4660<\/a><\/p>\n

Manual del Vacunador | Vacuna MODERNA para uso pedi\u00e1trico de 6 a 11 a\u00f1os
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2022-04\/manual-vacunador-moderna-desde-6-anos.pdf<\/a><\/p>\n

Manual del Vacunador | Segundo Refuerzo COVID-19
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2022-04\/covid-19-lineamientos-tecnicos-segundo-refuerzo.pdf<\/a><\/p>\n

El uso de corticoides inhalados para el tratamiento de COVID-19 podr\u00eda disminuir el riesgo de hospitalizaci\u00f3n o muerte y el tiempo de resoluci\u00f3n de s\u00edntomas
\nhttps:\/\/www.evidencia.org\/index.php\/Evidencia\/article\/view\/7007\/4676<\/a><\/p>\n

Memor\u00e1ndum | Consideraciones para la habilitaci\u00f3n de vacunaci\u00f3n contra Covid-19 para viajeros
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2022-03\/memorandum_17-03_Vacunas_exterior.pdf<\/a><\/p>\n

Baricitinib para el tratamiento de pacientes con COVID-19
\nhttps:\/\/www.argentina.gob.ar\/sites\/default\/files\/informe-rapido-covid-19-n15-baricitinib.pdf<\/a><\/p>\n

COVID-19 plant-based vaccines
\nhttps:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/covid19-industry\/drugs-vaccines-treatments\/vaccines\/plant-based.html<\/a><\/p>\n

La vacuna de ARN BNT162b2 frente a la COVID-19 parece segura y eficaz en ni\u00f1os mayores de 4 a\u00f1os
\nhttps:\/\/evidenciasenpediatria.es\/files\/41-14112-RUTA\/5_ACV_Vacuna_COVID.pdf<\/a><\/p>\n

Manual del vacunador. Vacuna Comirnaty de Pfizer-BioNTech pedi\u00e1trica de 5 a 11 a\u00f1os
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2022-03\/manual-pfizer-pediatrica.pdf<\/a><\/p>\n

Actualizaci\u00f3n de los Lineamientos T\u00e9cnicos | Resumen de recomendaciones vigentes para la Campa\u00f1a Nacional de Vacunaci\u00f3n contra la COVID-19
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2022-02\/lineamientos-tecnicos_unificado-covid19-2022.pdf<\/a><\/p>\n

Per\u00edodo de detecci\u00f3n de SARS-CoV2 a trav\u00e9s de PCR y Test de ant\u00edgenos
\nhttps:\/\/gacetamedica.com\/wp-content\/uploads\/2021\/02\/Periodo-de-detecci%C3%B3n-de-SARS-CoV-2-a-trav%C3%A9s-de-PCR-y-Test-de-ant%C3%ADgenos-2.pdf<\/a><\/p>\n

Nuevas condiciones de aislamiento
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2022-01\/nuevas-condiciones-aislamiento-covid-19_2022-01-18.pdf<\/a><\/p>\n

Recomendaci\u00f3n de vacunaci\u00f3n contra la COVID-19 en personas gestantes
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2022-01\/memo-personas-gestantes-11-01-22.pdf<\/a><\/p>\n

Adecuaci\u00f3n de las medidas para contactos estrechos de COVID-19
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2022-01\/comunicacion-medidas-ce.pdf<\/a><\/p>\n

Algoritmos de manejo de casos, contactos estrechos y personas sintom\u00e1ticas
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2022-01\/algoritmos-definiciones-covid19-2022.pdf<\/a><\/p>\n

Memor\u00e1ndum | \u00abRecomendaci\u00f3n de intervalo de dosis de refuerzo en personal de salud y mayores de 60 a\u00f1os\u00bb
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2021-12\/memo-dosis-de-refuerzo-4-meses-PS-y-mayores-de-60.pdf<\/a><\/p>\n

Memor\u00e1ndum: Recomendaci\u00f3n de intervalo para la aplicaci\u00f3n de la dosis de refuerzo de vacunas contra COVID-19
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2021-12\/memo%20Recomendacion%20de%20intervalo%20para%20aplicacion%20de%20la%20dosis%20de%20refuerzo%20Vacunas%20contra%20COVID-19.pdf<\/a><\/p>\n

INVESTIGACI\u00d3N REALIZADA POR PROFESIONALES DE LA\u00a0UNIDAD DE TERAPIA INTENSIVA<\/strong>\u00a0DE LA CL\u00cdNICA COL\u00d3N DE MAR DEL PLATA:
\nPulmonary Edema in COVID-19 Treated with Furosemide and Negative Fluid Balance (NEGBAL): A Different and Promising Approach
\nhttps:\/\/www.mdpi.com\/2077-0383\/10\/23\/5599\/htm<\/a><\/p>\n

SEXTO CONGRESO COLOMBIANO DE ATENCI\u00d3N FARMAC\u00c9UTICA: \u201cIDENTIFICANDO Y PROYECTANDO EL PAPEL DE LA ATENCI\u00d3N FARMAC\u00c9UTICA EN EL CONTEXTO DE LA POSPANDEMIA COVID-19
\nhttps:\/\/revistas.udea.edu.co\/index.php\/vitae\/article\/view\/348083\/20806693<\/a><\/p>\n

RECOMENDACIONES HIGI\u00c9NICO AMBIENTALES PARA LA FABRICACI\u00d3N DE PRODUCTOS M\u00c9DICOS EN EL CONTEXTO DE LA RECONVERSI\u00d3N DE INDUSTRIAS GENERADA POR LA PANDEMIA COVID-19
\nhttps:\/\/safybi.org\/wp-content\/uploads\/2021\/01\/GO-SAFYBI-003_Recomendaciones-higienico-ambientales-para-la-fabricacion-de-productos-medicos.v001.pdf<\/a><\/p>\n

Informe especial de vigilancia de seguridad en vacunas en ni\u00f1os, ni\u00f1as y adolescentes
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2021-11\/Informe_especial_de_vigilancia_de_seguridad_en_vacunas_en_ninios_ninas_adolescentes.pdf<\/a><\/p>\n

Gu\u00eda Cl\u00ednica Para La Atenci\u00f3n Al Paciente Long Covid\/Covid Persistente
\nhttps:\/\/www.semg.es\/images\/2021\/Documentos\/GUIA_CLINICA_COVID_Persistent_20210501_version_final.pdf<\/a><\/p>\n

Lineamientos t\u00e9cnicos: Dosis adicional al esquema primario y dosis de refuerzo (booster)
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2021-11\/lineamientos-tecnicos-COVID-19-booster.pdf<\/a><\/p>\n

Vacunas contra la COVID-19. Bolet\u00edn de errores de medicaci\u00f3n de Catalu\u00f1a
\nhttps:\/\/scientiasalut.gencat.cat\/bitstream\/handle\/11351\/6420\/butll_prev_errors_medicacio_catalunya_2021_19_01_cas.pdf?sequence=2&isAllowed=y<\/a><\/p>\n

RECOMENDACIONES PARA EL MANTENIMIENTO DE LAS BPF EN CONTEXTO DE COVID-19
\nhttps:\/\/safybi.org\/wp-content\/uploads\/2021\/01\/GO-SAFYBI-004_Recomendaciones-para-el-mantenimiento-de-las.BPF_.v001.pdf|<\/a><\/p>\n

Bloqueantes de receptores de angiotensina-II de novo para el tratamiento de pacientes con COVID-19
\nhttps:\/\/www.argentina.gob.ar\/sites\/default\/files\/informe-covid-19-n10-bloqueantes-receptores.pdf<\/a><\/p>\n

Lineamientos T\u00e9cnicos: Resumen de recomendaciones vigentes para la Campa\u00f1a Nacional de Vacunaci\u00f3n contra la COVID-19 | 7 de octubre de 2021
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2021-10\/LT%20COVID-19%20unificado%20Octubre.pdf<\/a><\/p>\n

Caracter\u00edsticas de las vacunas contra la COVID-19 disponibles en Argentina
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2021-10\/caracteristicas-de-las-vacunas-contra-la-COVID19-disponibles-en-argentina.pdf<\/a><\/p>\n

Vaxzevria (vacuna frente a la COVID-19 de AstraZeneca) y riesgo de s\u00edndrome de Guillain-Barr\u00e9
\nhttps:\/\/www.aemps.gob.es\/informa\/notasinformativas\/medicamentosusohumano-3\/seguridad-1\/2021-seguridad-1\/vaxzevria-y-riesgo-de-sindrome-de-guillain-barre\/<\/a><\/p>\n

Seroneutralizaci\u00f3n de variantes SARS-CoV-2 Gamma (P.1, Manaos), Alpha (B.1.1.7, Reino Unido) y Lambda (C.37, Andina) en individuos vacunados con Sputnik V e individuos recuperados de la infecci\u00f3n por SARS-CoV-2
\nhttp:\/\/pais.qb.fcen.uba.ar\/files\/reportes\/informe_seroneutralizacion_C37_P1.pdf<\/a><\/p>\n

EVALUACI\u00d3N DEL POTENCIAL NEUTRALIZANTE DE LOS ANTICUERPOS NATURALES Y LOS GENERADOS POR LAS VACUNAS ASTRAZENECA, SINOPHARM Y SPUTNIK V FRENTE A LA VARIANTE DE PREOCUPACI\u00d3N DELTA EN C\u00d3RDOBA
\nhttps:\/\/www.cba.gov.ar\/wp-content\/uploads\/2021\/09\/Informe-Delta-en-Co%CC%81rdoba-y-anticuerpos-neutralizantes-en-la-poblacio%CC%81n.pdf?csrt=6863230237421239545<\/a><\/p>\n

Recomendaciones para el diagn\u00f3stico y tratamiento del S\u00edndrome de Trombosis con Trombocitopenia tras la vacunaci\u00f3n frente a COVID-19
\nhttp:\/\/cime.fcq.unc.edu.ar\/wp-content\/uploads\/sites\/15\/2021\/09\/Bolet%C3%ADn-CIME-TTS-sept-2021-v.final_.pdf<\/a><\/p>\n

Tromboprofilaxis farmacol\u00f3gica frente a no trombofilaxis para el tratamiento de pacientes hospitalizados con COVID-19
\nhttps:\/\/www.argentina.gob.ar\/sites\/default\/files\/informe-covid-19-n8-tromboprofilaxis.pdf<\/a><\/p>\n

Manual del Vacunador. Vacuna Comirnaty de Pfizer-BioNTech
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2021-09\/manual-vacunador-pfizer.pdf<\/a><\/p>\n

COVID-19 Vaccine Media Hub
\nhttps:\/\/covidvaccinehub.org\/<\/a><\/p>\n

Ongoing Living Update of Potential COVID-19 Therapeutics Options: Summary of Evidence. Rapid Review
\nhttps:\/\/iris.paho.org\/handle\/10665.2\/52719<\/a><\/p>\n

Manual del Vacunador. Vacuna CONVIDECIA
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2021-09\/manual-vacunador-vacuna-convidecia-2021-septiembre.pdf<\/a><\/p>\n

Azitromicina para el tratamiento de pacientes con COVID-19
\nhttps:\/\/www.argentina.gob.ar\/sites\/default\/files\/informe-covid-19-n9-azitromicina.pdf<\/a><\/p>\n

Tracking the vaccine race: A look at the vaccines in development to fight COVID-19.
\nhttps:\/\/graphics.reuters.com\/HEALTH-CORONAVIRUS\/VACCINE-TRACKER\/xegpbqnlovq\/<\/a><\/p>\n

Ibuprofeno inhalado para el tratamiento de pacientes con COVID-19
\nhttps:\/\/www.argentina.gob.ar\/sites\/default\/files\/informe-covid-19-n12-ibuprofeno-inhalado.pdf<\/a><\/p>\n

RECOMENDACI\u00d3N SOBRE ESQUEMAS HETER\u00d3LOGOS DE VACUNACI\u00d3N COVID-19
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2021-08\/recomendacion-sobre-esquemas-heterologos-de-vacunacion-contra-COVID19.pdf<\/a><\/p>\n

Manual del Vacunador. Vacuna Moderna – 28 de julio de 2021
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2021-07\/Manual%20vacunador%20MODERNA.pdf<\/a><\/p>\n

Spikevax1(vacuna de ARNm contra la COVID-19 [nucle\u00f3sidos modificados])
\nhttps:\/\/www.ema.europa.eu\/en\/documents\/overview\/spikevax-previously-covid-19-vaccine-moderna-epar-medicine-overview_es.pdf<\/a><\/p>\n

Recomendaciones para el Abordaje Terap\u00e9utico de Covid-19 en Ni\u00f1os, Ni\u00f1as y Adolescentes
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2021-07\/abordaje-nnya-covid_0.pdf<\/a><\/p>\n

Farmacovigilancia de vacunas para COVID-19
\nhttps:\/\/covid-19pharmacovigilance.paho.org\/index.php<\/a><\/p>\n

Clinical trials: COVID-19
\nhttps:\/\/www.recoverytrial.net\/results<\/a><\/p>\n

COVID-19 PREVENCI\u00d3N DE TRANSMISI\u00d3N POR AEROSOLES RECOMENDACIONES
\nhttps:\/\/www.argentina.gob.ar\/sites\/default\/files\/covid-19-prevencion-de-transmision-por-aerosoles-2021_0.pdf<\/a><\/p>\n

Gu\u00eda provisional de la ISTH para el diagn\u00f3stico y el tratamiento de la trombocitopenia tromb\u00f3tica inmune inducida por vacunas (TTIIV) (actualizada el 20 de Abril de 2021)
\nhttps:\/\/cdn.ymaws.com\/www.isth.org\/resource\/resmgr\/ISTH_VITT_Spanish_Guidance_F.pdf<\/a><\/p>\n

Empleo de la vacuna Sputnik V en Argentina: Evaluaci\u00f3n de respuesta humoral frente a la vacunaci\u00f3n. Informe Final Enero\u2010Marzo 2021
\nhttps:\/\/www.conicet.gov.ar\/wp-content\/uploads\/Informe-Sputnik_Buenos-Aires-13.04.2021..pdf<\/a><\/p>\n

Ivermectina para el tratamiento de pacientes con COVID-19 y expuestos al SARS-CoV-2
\nhttps:\/\/www.argentina.gob.ar\/sites\/default\/files\/informe-covid-19-n14-ivermectina.pdf<\/a><\/p>\n

Esteroides sist\u00e9micos para el tratamiento de pacientes con COVID-19
\nhttps:\/\/www.argentina.gob.ar\/sites\/default\/files\/informe-covid-19-n3-esteroides.pdf<\/a><\/p>\n

Vacuna frente al COVID-19
\nhttps:\/\/seq.es\/wp-content\/uploads\/2021\/04\/vacunas-covid-4.5.pdf<\/a><\/p>\n

Ficha t\u00e9cnica de VITAMINA D (RACIM)
\nhttp:\/\/cime.fcq.unc.edu.ar\/wp-content\/uploads\/sites\/15\/2020\/12\/RACIM-Vitamina-D-versi%C3%B3n-2-18.11.2020.pdf<\/a><\/p>\n

Ficha t\u00e9cnica de VITAMINA C (RACIM)
\nhttp:\/\/cime.fcq.unc.edu.ar\/wp-content\/uploads\/sites\/15\/2020\/09\/RACIM-Vit-C-versi%C3%B3n-1-01.07.2020-1.pdf<\/a><\/p>\n

Suplementos vitam\u00ednicos (Vit. C, D) y Zinc en infecci\u00f3n por COVID-19
\nhttps:\/\/www.iecs.org.ar\/wp-content\/uploads\/IECS-IRR-788-Suplementos-vitami%CC%81nicos-y-Zinc-en-COVID-1.pdf<\/a><\/p>\n

Ivermectina para COVID-19
\nhttps:\/\/www.iecs.org.ar\/wp-content\/uploads\/IECS-IRR-823-VA.pdf<\/a><\/p>\n

RACIM de ivermectina (actualizaci\u00f3n de la versi\u00f3n 3)
\nhttps:\/\/www.fundacionfemeba.org.ar\/blog\/farmacologia-7\/post\/racim-ivermectina-en-covid19-actualizacion-48807<\/a><\/p>\n

Actualizaci\u00f3n del manual del vacunador de Sputnik V
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2021-02\/actualizacion-manual-vacunador-sputnik-v-10-02-21.pdf<\/a><\/p>\n

Manual vacunador Sinopharm
\nhttps:\/\/bancos.salud.gob.ar\/sites\/default\/files\/2021-03\/manual-vacunador-sinopharm_12-3-2021.pdf<\/a><\/p>\n

Evaluaci\u00f3n del riesgo por contagio de coronavirus SARS-CoV-2 y medidas preventivas recomendadas en la prestaci\u00f3n de servicios profesionales farmac\u00e9uticos asistenciales (SPFA)
\nhttps:\/\/www.sefac.org\/system\/files\/2020-06\/Documento%20SEFAC%20evaluaci%C3%B3n%20de%20riesgos%20en%20SPFA%20y%20coronavirus_0.pdf<\/a><\/p>\n

Ventilaci\u00f3n y COVID-19 en la Industria
\nhttps:\/\/www.argentina.gob.ar\/sites\/default\/files\/ficha_tecnica_ventilacion_y_covid_150920.pdf<\/a><\/p>\n

COVID-19: Acciones regulatorias de ANMAT
\nhttps:\/\/www.argentina.gob.ar\/anmat\/covid-19-acciones-regulatorias-de-anmat<\/a><\/p>\n

PROTOCOLO DE ACTUACI\u00d3N DESDE LAS FARMACIAS COMUNITARIAS
\nhttps:\/\/www.colfacor.org.ar\/administrador_web\/kcfinder\/upload\/files\/info_coronavirus_farmacias%284%29.pdf<\/a><\/p>\n

Impacto<\/em>\u00a0de los\u00a0sistemas<\/em>\u00a0de\u00a0ventilaci\u00f3n<\/em>\u00a0en la\u00a0transmisi\u00f3n<\/em>\u00a0del\u00a0SARS<\/em>\u2013CoV<\/em>\u20132<\/em>.\u00a0Recomendaciones generales para<\/em>\u00a0los\u00a0edificios<\/em>\u00a0de\u00a0uso p\u00fablico
\n<\/em>https:\/\/www.comunidad.madrid\/sites\/default\/files\/doc\/sanidad\/samb\/doc_tec_ventilacion_el_sars-cov-2.pdf<\/em><\/a><\/p>\n

Draft landscape of COVID-19 candidate vaccines
\nhttps:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines<\/a><\/p>\n

COVID-19INTERACCIONES MEDICAMENTOSAS
\nhttps:\/\/www.argentina.gob.ar\/sites\/default\/files\/covid-19_interacciones-medicamentosas.pdf<\/a><\/p>\n

 <\/p>\n

Art\u00edculos cient\u00edficos<\/h2>\n

M\u00faltiples reacciones adversas graves a f\u00e1rmacos en un paciente luego de la infecci\u00f3n por COVID-19. Informe de un caso
\nhttps:\/\/ojs.hospitalitaliano.org.ar\/index.php\/revistahi\/article\/view\/260\/134<\/a><\/p>\n

Allergists and COVID-vaccine: which is the actual risk of reactions in allergic patients?
\nhttps:\/\/www.mattioli1885journals.com\/index.php\/actabiomedica\/article\/view\/13006\/11057<\/a><\/p>\n

Association of Symptoms After COVID-19 Vaccination With Anti\u2013SARS-CoV-2 Antibody Response in the Framingham Heart Study
\nhttps:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2797552<\/a><\/p>\n

Duration of immunity following full vaccination against SARS-CoV-2: a systematic review
\nhttps:\/\/archpublichealth.biomedcentral.com\/counter\/pdf\/10.1186\/s13690-022-00935-x.pdf<\/a><\/p>\n

Comparative effectiveness of N95, surgical or medical, and non-medical facemasks in protection against respiratory virus infection: A systematic review and network meta-analysis
\nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9111143\/pdf\/RMV-32-0.pdf<\/a><\/p>\n

Antiviral Activity of Echinacea Extract Appears to Include SARS-CoV-2
\nhttps:\/\/www.herbalgram.org\/media\/17794\/032223.pdf<\/a><\/p>\n

SARS-CoV-2-Specific IgG and IgA response in maternal blood and breastmilk of vaccinated na\u00efve and convalescent lactating participants
\nhttps:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.909995\/pdf<\/a><\/p>\n

Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2209367?articleTools=true<\/a><\/p>\n

Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England
\nhttps:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2797625\/strasser_2022_oi_221086_1666016864.51241.pdf<\/a><\/p>\n

Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
\nhttps:\/\/www.science.org\/doi\/epdf\/10.1126\/science.abo2523<\/a><\/p>\n

A multinational Delphi consensus to end the COVID-19 public health threat
\nhttps:\/\/www.nature.com\/articles\/s41586-022-05398-2.pdf<\/a><\/p>\n

Gout and Excess Risk of Severe SARS-CoV-2 Infection Among Vaccinated Individuals: A General Population Study
\nhttps:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.42339<\/a><\/p>\n

S\u00edndrome de Gianotti-Crosti de localizaci\u00f3n at\u00edpica en un adulto despu\u00e9s de la vacunaci\u00f3n contra el SARS-CoV-2
\nhttps:\/\/www.actasdermo.org\/es-pdf-S0001731023000443<\/a><\/p>\n

SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia
\nhttps:\/\/bmcmedicine.biomedcentral.com\/counter\/pdf\/10.1186\/s12916-022-02547-2.pdf<\/a><\/p>\n

Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies
\nhttps:\/\/www.thelancet.com\/pdfs\/journals\/laninf\/PIIS1473-3099(22)00663-6.pdf<\/a><\/p>\n

Stevens-Johnson syndrome related with Comirnaty\u00ae coronavirus disease 2019 vaccine
\nhttps:\/\/www.scienceopen.com\/document_file\/3455a93b-637b-4964-8372-8a06712968c6\/PubMedCentral\/3455a93b-637b-4964-8372-8a06712968c6.pdf<\/a><\/p>\n

Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants
\nhttps:\/\/www.nejm.org\/doi\/10.1056\/NEJMc2209306<\/a><\/p>\n

Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial
\nhttps:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2797483<\/a><\/p>\n

UTILIZACI\u00d3N PRECOZ DE TOCILIZUMAB EN PACIENTES INTERNADOS CON COVID-19 GRAVE Y CR\u00cdTICA: UN ESTUDIO MULTIC\u00c9NTRICO EN LA PROVINCIA DE BUENOS AIRES
\nhttps:\/\/www.medicinabuenosaires.com\/revistas\/vol83-23\/original_7941.pdf<\/a><\/p>\n

Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMc2212117?articleTools=true<\/a><\/p>\n

Shoulder injury related to vaccine administration (SIRVA): What do we know about its incidence and impact?
\nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9576975\/pdf\/main.pdf<\/a><\/p>\n

Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial
\nhttps:\/\/www.bmj.com\/content\/bmj\/379\/bmj-2022-072175.full.pdf<\/a><\/p>\n

Hypertension and Excess Risk for Severe COVID-19 Illness Despite Booster Vaccination
\nhttps:\/\/www.ahajournals.org\/doi\/pdf\/10.1161\/HYPERTENSIONAHA.122.19694<\/a><\/p>\n

Mechanisms of COVID-19 pathogenesis in diabetes
\nhttps:\/\/journals.physiology.org\/doi\/epdf\/10.1152\/ajpheart.00204.2022<\/a><\/p>\n

Efficacy of Combined Visual-Olfactory Training With Patient-Preferred Scents as Treatment for Patients With COVID-19 Resultant Olfactory Loss
\nA Randomized Clinical Trial
\nhttps:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/fullarticle\/2799843<\/a><\/p>\n

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMc2214302?articleTools=true<\/a><\/p>\n

Comparative Risk of Myocarditis\/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines
\nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9639791\/pdf\/main.pdf<\/a><\/p>\n

Primary hypertension, anti-hypertensive medications and the risk of severe COVID-19 in UK Biobank
\nhttps:\/\/journals.plos.org\/plosone\/article\/file?id=10.1371\/journal.pone.0276781&type=printable<\/a><\/p>\n

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2118542?articleTools=true<\/a><\/p>\n

Efficacy of olive leaves extract on the outcomes of hospitalized covid-19 patients: A randomized, triple-blinded clinical trial
\nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9617633\/pdf\/main.pdf<\/a><\/p>\n

Examination of Adverse Reactions After COVID-19 Vaccination Among Patients With a History of Multisystem Inflammatory Syndrome in Children
\nhttps:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2799939<\/a><\/p>\n

Gout and Excess Risk of Severe SARS-CoV-2 Infection Among Vaccinated Individuals: A General Population Study
\nhttps:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.42339<\/a><\/p>\n

Covid-19 Vaccine Protection among Children and Adolescents in Qatar
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2210058?articleTools=true<\/a><\/p>\n

Therapeutic advances in COVID-19
\nhttps:\/\/www.nature.com\/articles\/s41581-022-00642-4.pdf<\/a><\/p>\n

Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US
\nhttps:\/\/www.bmj.com\/content\/bmj\/379\/bmj-2022-071594.full.pdf<\/a><\/p>\n

Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMc2211283?articleTools=true<\/a><\/p>\n

Humoral response and neutralising capacity at 6 months post-vaccination against COVID-19 among institutionalised older adults in Argentina
\nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9549602\/pdf\/fimmu-13-992370.pdf<\/a><\/p>\n

SARS-CoV-2-Specific IgG and IgA response in maternal blood and breastmilk of vaccinated na\u00efve and convalescent lactating participants
\nhttps:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.909995\/pdf<\/a><\/p>\n

Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2209367?articleTools=true<\/a><\/p>\n

Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England
\nhttps:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2797625\/strasser_2022_oi_221086_1666016864.51241.pdf<\/a><\/p>\n

Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
\nhttps:\/\/www.science.org\/doi\/epdf\/10.1126\/science.abo2523<\/a><\/p>\n

A multinational Delphi consensus to end the COVID-19 public health threat
\nhttps:\/\/www.nature.com\/articles\/s41586-022-05398-2.pdf<\/a><\/p>\n

ETF statement on the loss of activity of anti-spike protein monoclonal antibodies due to emerging SARS-CoV-2 variants of concern
\nhttps:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/etf-statement-loss-activity-anti-spike-protein-monoclonal-antibodies-due-emerging-sars-cov-2_en.pdf<\/a><\/p>\n

Allergists and COVID-vaccine: which is the actual risk of reactions in allergic patients?
\nhttps:\/\/www.mattioli1885journals.com\/index.php\/actabiomedica\/article\/view\/13006\/11057<\/a><\/p>\n

Association of Symptoms After COVID-19 Vaccination With Anti\u2013SARS-CoV-2 Antibody Response in the Framingham Heart Study
\nhttps:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2797552<\/a><\/p>\n

Duration of immunity following full vaccination against SARS-CoV-2: a systematic review
\nhttps:\/\/archpublichealth.biomedcentral.com\/counter\/pdf\/10.1186\/s13690-022-00935-x.pdf<\/a><\/p>\n

Comparative effectiveness of N95, surgical or medical, and non-medical facemasks in protection against respiratory virus infection: A systematic review and network meta-analysis
\nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9111143\/pdf\/RMV-32-0.pdf<\/a><\/p>\n

Antiviral Activity of Echinacea Extract Appears to Include SARS-CoV-2
\nhttps:\/\/www.herbalgram.org\/media\/17794\/032223.pdf<\/a><\/p>\n

COVID-19 vaccines reduce the risk of SARS-CoV-2 reinfection and hospitalization: Meta-analysis
\nhttps:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1023507\/pdf<\/a><\/p>\n

SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia
\nhttps:\/\/bmcmedicine.biomedcentral.com\/counter\/pdf\/10.1186\/s12916-022-02547-2.pdf<\/a><\/p>\n

Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies
\nhttps:\/\/www.thelancet.com\/pdfs\/journals\/laninf\/PIIS1473-3099(22)00663-6.pdf<\/a><\/p>\n

Stevens-Johnson syndrome related with Comirnaty\u00ae coronavirus disease 2019 vaccine
\nhttps:\/\/www.scienceopen.com\/document_file\/3455a93b-637b-4964-8372-8a06712968c6\/PubMedCentral\/3455a93b-637b-4964-8372-8a06712968c6.pdf<\/a><\/p>\n

Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants
\nhttps:\/\/www.nejm.org\/doi\/10.1056\/NEJMc2209306<\/a><\/p>\n

Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial
\nhttps:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2797483<\/a><\/p>\n

SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia
\nhttps:\/\/bmcmedicine.biomedcentral.com\/counter\/pdf\/10.1186\/s12916-022-02547-2.pdf<\/a><\/p>\n

Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies
\nhttps:\/\/www.thelancet.com\/pdfs\/journals\/laninf\/PIIS1473-3099(22)00663-6.pdf<\/a><\/p>\n

Stevens-Johnson syndrome related with Comirnaty\u00ae coronavirus disease 2019 vaccine
\nhttps:\/\/www.scienceopen.com\/document_file\/3455a93b-637b-4964-8372-8a06712968c6\/PubMedCentral\/3455a93b-637b-4964-8372-8a06712968c6.pdf<\/a><\/p>\n

Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants
\nhttps:\/\/www.nejm.org\/doi\/10.1056\/NEJMc2209306<\/a><\/p>\n

Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial
\nhttps:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2797483<\/a><\/p>\n

Allergists and COVID-vaccine: which is the actual risk of reactions in allergic patients?
\nhttps:\/\/www.mattioli1885journals.com\/index.php\/actabiomedica\/article\/view\/13006\/11057<\/a><\/p>\n

Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality
\nin children in Argentina, during predominance of delta and omicron covid-19 variants: test
\nnegative, case-control study
\nhttps:\/\/www.bmj.com\/content\/bmj\/379\/bmj-2022-073070.full.pdf\u00a0<\/a><\/p>\n

Aportes de la biotecnolog\u00eda en el diagn\u00f3stico de COVID-19
\nhttps:\/\/ojs.hospitalitaliano.org.ar\/index.php\/revistahi\/article\/view\/204\/105<\/a><\/p>\n

Adverse drug reactions reported following use of oral COVID-19 therapeutics in New Zealand
\nhttps:\/\/www.medsafe.govt.nz\/profs\/PUArticles\/December2022\/Adverse-drug-reactions-reported-
\noral-COVID-19-therapeutics.html<\/p>\n

Association of mRNA Vaccination With Clinical and Virologic Features of COVID-19 Among US
\nEssential and Frontline Workers
\nhttps:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2797418?utm_source=substack&amp;utm_mediu<\/a>
\nm=email<\/p>\n

What next for covid-19 vaccines?
\nhttps:\/\/www.bmj.com\/content\/379\/bmj.o2422?utm_source=substack&amp;utm_medium=email<\/a><\/p>\n

Enfermedades dermatol\u00f3gicas inmunomediadas desencadenadas por la infecci\u00f3n por SARS-CoV-2
\nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9500085\/pdf\/main.pdf<\/a><\/p>\n

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
\nhttps:\/\/www.thelancet.com\/pdfs\/journals\/ebiom\/PIIS2352-3964(22)00480-7.pdf<\/a><\/p>\n

Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults
\nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9428332\/pdf\/main.pdf<\/a><\/p>\n

Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2209367?articleTools=true<\/a><\/p>\n

COVID-19 Diagnosis and Risk of Death Among Adults With Cancer in Indiana: Retrospective Cohort Study
\nhttps:\/\/cancer.jmir.org\/2022\/4\/e35310\/PDF<\/a><\/p>\n

An\u00e1lisis de las reacciones adversas a la vacuna contra COVID-19 en la poblaci\u00f3n de la Zona B\u00e1sica de Salud de Cantalejo
\nhttps:\/\/mgyf.org\/wp-content\/uploads\/2022\/11\/MGYF2022_046-1.pdf<\/a><\/p>\n

Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States
\nhttps:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2796667?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=092622<\/a><\/p>\n

Association of Frailty, Age, and Biological Sex With Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine\u2013Induced Immunity in Older Adults
\nhttps:\/\/academic.oup.com\/cid\/article-pdf\/75\/Supplement_1\/S61\/45407502\/ciac397.pdf<\/a><\/p>\n

Association Between Vaccination Status and Mortality Among Intubated Patients With COVID-19\u2013Related Acute Respiratory Distress Syndrome
\nhttps:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2797179<\/a><\/p>\n

Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era
\nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9575390\/pdf\/aim-olf-M221856.pdf<\/a><\/p>\n

Association between menstrual cycle length and covid-19 vaccination: global, retrospective cohort study of prospectively collected data
\nhttps:\/\/bmjmedicine.bmj.com\/content\/bmjmed\/1\/1\/e000297.full.pdf<\/a><\/p>\n

Multi-Disciplinary Collaborative Consensus Guidance Statement on the Assessment and Treatment of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) in Children and Adolescents
\nhttps:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pmrj.12890<\/a><\/p>\n

Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review
\nhttps:\/\/www.thelancet.com\/action\/showPdf?pii=S2589-5370%2822%2900354-6<\/a><\/p>\n

Reaction of SARS-CoV-2 antibodies with other pathogens, vaccines, and food antigens
\nhttps:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1003094\/pdf<\/a><\/p>\n

Biosynthetic proteins targeting the SARS-CoV-2 spike as anti-virals
\nhttps:\/\/journals.plos.org\/plospathogens\/article\/file?id=10.1371\/journal.ppat.1010799&type=printable<\/a><\/p>\n

Vaccine-Induced Immune Thrombocytopenia and Thrombosis after the Sputnik V Vaccine
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMc2210813?articleTools=true<\/a><\/p>\n

Association of COVID-19 Vaccination During Early Pregnancy With Risk of Congenital Fetal Anomalies
\nhttps:\/\/jamanetwork.com\/journals\/jamapediatrics\/fullarticle\/2790805<\/a><\/p>\n

Hypersensitivity Reactions to COVID-19 Vaccines\u2014Identify High-risk Children and Vaccinate the Rest
\nhttps:\/\/jamanetwork.com\/journals\/jamapediatrics\/fullarticle\/2789414<\/a><\/p>\n

Durability of Anti-Spike Antibodies in Infants After Maternal COVID-19 Vaccination or Natural Infection
\nhttps:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2788986<\/a><\/p>\n

Effects of Vaccination and Previous Infection on Omicron Infections in Children
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMc2209371?articleTools=true<\/a><\/p>\n

Analysis of Vaccine Reactions After COVID-19 Vaccine Booster Doses Among Pregnant and Lactating Individuals
\nhttps:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2795998<\/a><\/p>\n

Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: a multi-center prospective observational study
\nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9360656\/pdf\/10549_2022_Article_6693.pdf<\/a><\/p>\n

De las publicaciones a la pr\u00e1ctica cotidiana: tocilizumab en pacientes con COVID-19 grave
\nhttps:\/\/www.medicinabuenosaires.com\/revistas\/vol82-22\/n5\/659.pdf<\/a><\/p>\n

Association of Male Hypogonadism With Risk of Hospitalization for COVID-19
\nhttps:\/\/pubmed.ncbi.nlm.nih.gov\/36053534\/<\/a><\/p>\n

Severity of COVID-19 among solid organ transplant recipients in Canada, 2020\u20132021: a prospective, multicentre cohort study
\nhttps:\/\/www.cmaj.ca\/content\/cmaj\/194\/33\/E1155.full.pdf<\/a><\/p>\n

Effect of pneumococcal conjugate vaccines and SARS-CoV-2 on antimicrobial resistance and the emergence of Streptococcus pneumoniae serotypes with reduced susceptibility in Spain, 2004\u201320: a national surveillance study
\nhttps:\/\/www.thelancet.com\/action\/showPdf?pii=S2666-5247%2822%2900127-6<\/a><\/p>\n

Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT)
\nhttps:\/\/www.bmj.com\/content\/bmj\/378\/bmj-2022-071230.full.pdf<\/a><\/p>\n

Assessment of Delayed Large Local Reactions After the First Dose of the SARS-CoV-2 mRNA-1273 Vaccine in Japan
\nhttps:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2792873<\/a><\/p>\n

Risk of Appendicitis After mRNA COVID-19 Vaccination in a Danish Population
\nhttps:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2791667<\/a><\/p>\n

Evaluation of Acute Adverse Events after Covid-19 Vaccination during Pregnancy
\nhttps:\/\/www.nejm.org\/doi\/10.1056\/NEJMc2205276<\/a><\/p>\n

S\u00edndrome de Guillain-Barr\u00e9 y trombocitopenia tras la vacunaci\u00f3n contra el SARS-CoV-2 con Moderna. Descripci\u00f3n de un caso
\nhttps:\/\/neurologia.com\/articulo\/2022138<\/a><\/p>\n

Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the Omicron outbreak in adults of 50 years and older in Argentina: a test-negative case-control study
\nhttps:\/\/www.medrxiv.org\/content\/10.1101\/2022.09.25.22280341v2<\/a><\/p>\n

Patients\u00a0 with previous presumed immediate hypersensitivity\u00a0 reactions\u00a0 to polyethylene glycol (PEG)\u00a0 can safely\u00a0 receive the Pfizer BioNTech\u00a0 BNT162b2 COVID-19\u00a0 vaccine
\nhttps:\/\/onlinelibrary.wiley.com\/doi\/epdf\/10.1111\/imj.15821?utm_source=substack&utm_medium=email<\/a><\/p>\n

Folic acid and methotrexate use and their association with COVID-19 diagnosis and mortality: a case\u2013control analysis from the UK Biobank
\nhttps:\/\/bmjopen.bmj.com\/content\/bmjopen\/12\/8\/e062945.full.pdf<\/a><\/p>\n

Myocarditis After\u00a0BNT162b2<\/em>\u00a0COVID-19 Third Booster Vaccine in Israel
\nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9439627\/pdf\/cir-146-802.pdf<\/a><\/p>\n

Prevention of covid-19 and other acute respiratory infections with cod liver oil supplementation, a low dose vitamin D supplement: quadruple blinded, randomised placebo controlled trial
\nhttps:\/\/www.bmj.com\/content\/bmj\/378\/bmj-2022-071245.full.pdf<\/a><\/p>\n

Can vitamin D protect against covid-19?
\nhttps:\/\/www.bmj.com\/content\/bmj\/378\/bmj.o1822.full.pdf<\/a><\/p>\n

Humoral and cellular immune response over 9 months of mRNA-1273, BNT162b2 and ChAdOx1 vaccination in a University Hospital in Spain
\nhttps:\/\/www.nature.com\/articles\/s41598-022-19537-2.pdf<\/a><\/p>\n

Multiple BCG vaccinations for the prevention of COVID-19 and other infectious diseases in type 1 diabetes
\nhttps:\/\/www.cell.com\/action\/showPdf?pii=S2666-3791%2822%2900271-3<\/a><\/p>\n

Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex
\nhttps:\/\/www.ahajournals.org\/doi\/epdf\/10.1161\/CIRCULATIONAHA.122.059970<\/a><\/p>\n

Association of Reduced Hospitalizations and Mortality Rates Among COVID-19-Vaccinated Patients With Heart Failure
\nhttps:\/\/www.onlinejcf.com\/action\/showPdf?pii=S1071-9164%2822%2900536-X<\/a><\/p>\n

COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology
\nhttps:\/\/onlinelibrary.wiley.com\/doi\/epdf\/10.1002\/ejhf.2356<\/a><\/p>\n

Risk of preterm birth, small for gestational age at birth, and stillbirth after covid-19 vaccination during pregnancy: population based retrospective cohort study
\nhttps:\/\/www.bmj.com\/content\/bmj\/378\/bmj-2022-071416.full.pdf<\/a><\/p>\n

Covid-19: Severe complications during pregnancy are more common in unvaccinated women, study finds
\nhttps:\/\/www.bmj.com\/content\/bmj\/376\/bmj.o117.full.pdf<\/a><\/p>\n

Factores asociados a la anosmia y ageusia en pacientes COVID-19de una provincia peruana
\nhttps:\/\/revistas.udea.edu.co\/index.php\/iatreia\/article\/view\/346608\/20807098<\/a><\/p>\n

SARS-CoV-2-Specific IgG and IgA response in maternal blood and breastmilk of vaccinated na\u00efve and convalescent lactating participants
\nhttps:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.909995\/pdf<\/a><\/p>\n

From publications to every day clinical practice: tocilizumab in patients with severe covid-19
\nhttps:\/\/www.medicinabuenosaires.com\/revistas\/vol82-22\/destacado\/original_7760.pdf<\/a><\/p>\n

Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers
\nhttps:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2794072<\/a><\/p>\n

Olfactory dysfunction but not COVID-19 severity predicts severity of cognitive sequelae following SARS-CoV-2 infection in Amerindian older adults
\nhttps:\/\/alz.confex.com\/alz\/2022\/meetingapp.cgi\/Paper\/66868<\/a><\/p>\n

Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2201662?articleTools=true<\/a><\/p>\n

Association of Homologous and Heterologous Vaccine Boosters With SARS-CoV-2 Infection in BBIBP-CorV Vaccinated Healthcare Personnel
\nhttps:\/\/www.cureus.com\/articles\/103631-association-of-homologous-and-heterologous-vaccine-boosters-with-sars-cov-2-infection-in-bbibp-corv-vaccinated-healthcare-personnel<\/a><\/p>\n

Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals
\nhttps:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-022-01027-6.pdf<\/a><\/p>\n

Respuesta humoral inducida por la vacuna BBIBP-CorV\/Sinopharm COVID-19 en trabajadores de primera l\u00ednea
\nhttp:\/\/iaes.edu.ve\/iaespro\/ojs\/index.php\/bmsa\/article\/view\/494\/681<\/a><\/p>\n

A Bivalent Omicron-Containing Booster Vaccine against Covid-19
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2208343?articleTools=true<\/a><\/p>\n

Covid-19 vaccine does not affect sustained implantation rates after single euploid embryo transfer, a retrospective study with 4868 cases
\nhttps:\/\/academic.oup.com\/humrep\/article\/37\/Supplement_1\/deac105.038\/6619730<\/a><\/p>\n

Placental pathology in women vaccinated and unvaccinated against SARS-CoV-2
\nhttps:\/\/www.ajog.org\/action\/showPdf?pii=S0002-9378%2822%2900515-4<\/a><\/p>\n

A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine
\nhttps:\/\/journals.asm.org\/doi\/epdf\/10.1128\/mbio.01822-22<\/a><\/p>\n

Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records
\nhttps:\/\/www.bmj.com\/content\/bmj\/378\/bmj-2022-071249.full.pdf<\/a><\/p>\n

Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study
\nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9257064\/pdf\/bmj-2022-071502.pdf<\/a><\/p>\n

COVID-19 VACCINE COMPARISON CHART from The Medical Letter
\nhttps:\/\/secure.medicalletter.org\/downloads\/1621g_table.pdf<\/a><\/p>\n

Covid-19 Vaccines \u2014 Immunity, Variants, Boosters
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMra2206573?articleTools=true<\/a><\/p>\n

Vaccine-Induced Immune Thrombocytopenia and Thrombosis after the Sputnik V Vaccine
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMc2210813?articleTools=true<\/a><\/p>\n

Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US
\nhttps:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2794318<\/a><\/p>\n

Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis
\nhttps:\/\/www.cmaj.ca\/content\/cmaj\/194\/28\/E969.full.pdf<\/a><\/p>\n

Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2203209?articleTools=true<\/a><\/p>\n

Social impact of the clinical trials on COVID-19-related vaccines and other drugs
\nhttps:\/\/www.esteve.org\/capitulos\/social-impact-of-the-clinical-trials-on-covid-19-related-vaccines-and-other-drugs-2\/<\/a><\/p>\n

Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMc2210546?articleTools=true<\/a><\/p>\n

Myocarditis and pericarditis have been reported with Nuvaxovid (Novavax COVID-19 Vaccine)
\nhttps:\/\/www.medsafe.govt.nz\/safety\/Alerts\/nuvaxovid-myocarditis.asp<\/a><\/p>\n

Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City
\nhttps:\/\/www.thelancet.com\/action\/showPdf?pii=S2665-9913%2822%2900190-4<\/a><\/p>\n

Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases
\nhttps:\/\/www.gastrojournal.org\/action\/showPdf?pii=S0016-5085%2822%2900450-4<\/a><\/p>\n

Relationship between ABO Blood Group Distribution and COVID-19 Infection in Patients Admitted to the ICU: A Multicenter Observational Spanish Study
\nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9181327\/pdf\/jcm-11-03042.pdf<\/a><\/p>\n

Investigating trends in those who experience menstrual bleeding changes after SARS-CoV-2 vaccination
\nhttps:\/\/www.science.org\/doi\/epdf\/10.1126\/sciadv.abm7201<\/a><\/p>\n

Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
\nhttps:\/\/www.nature.com\/articles\/s41421-022-00435-w.pdf<\/a><\/p>\n

Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination
\nhttps:\/\/www.science.org\/doi\/epdf\/10.1126\/sciimmunol.add4853<\/a><\/p>\n

Venous Thromboembolism Prophylaxis in COVID-19: Making Sense of the Evidence
\nhttps:\/\/www.acpjournals.org\/doi\/10.7326\/M22-1425<\/a><\/p>\n

Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis
\nhttps:\/\/evidence.nejm.org\/doi\/pdf\/10.1056\/EVIDoa2200145<\/a><\/p>\n

Outcomes of SARS-CoV-2 Reinfection
\nhttps:\/\/www.researchsquare.com\/article\/rs-1749502\/v1<\/a><\/p>\n

Multisystem Inflammatory Syndrome Temporally Related to COVID-19 in Children From Latin America and the Caribbean Region: A Systematic Review With a Meta-Analysis of Data From Regional Surveillance Systems
\nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9082071\/pdf\/fped-10-881765.pdf<\/a><\/p>\n

A Fourth Dose of COVID-19 Vaccine Does Not Induce Neutralization of the Omicron Variant Among Solid Organ Transplant Recipients With Suboptimal Vaccine Response
\nhttps:\/\/journals.lww.com\/transplantjournal\/Fulltext\/2022\/07000\/A_Fourth_Dose_of_COVID_19_Vaccine_Does_Not_Induce.22.aspx<\/a><\/p>\n

Covid-19 Vaccines \u2014 Immunity, Variants, Boosters
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMra2206573?articleTools=true<\/a><\/p>\n

Two new oral antivirals for covid-19: molnupiravir and nirmatrelvir plus ritonavir
\nhttps:\/\/dtb.bmj.com\/content\/dtb\/60\/5\/73.full.pdf<\/a><\/p>\n

Caracterizaci\u00f3n de las manifestaciones cut\u00e1neas por infecci\u00f3n de SARS-COV-2 en pacientes de Am\u00e9rica Latina
\nhttps:\/\/www.elsevier.es\/es-revista-piel-formacion-continuada-dermatologia-21-pdf-S0213925122001083<\/a><\/p>\n

Reactivaci\u00f3n del virus varicela z\u00f3ster tras la vacunaci\u00f3n contra la COVID-19
\nhttps:\/\/www.elsevier.es\/es-revista-piel-formacion-continuada-dermatologia-21-pdf-S021392512200137X<\/a><\/p>\n

Lesiones acroisqu\u00e9micas tras la vacunaci\u00f3n contra la COVID-19
\nhttps:\/\/www.elsevier.es\/es-revista-piel-formacion-continuada-dermatologia-21-pdf-S0213925122000582<\/a><\/p>\n

Vasculitis leucocitocl\u00e1stica asociada a la vacuna ARNm contra la COVID-19
\nhttps:\/\/www.elsevier.es\/es-revista-piel-formacion-continuada-dermatologia-21-pdf-S0213925122001381<\/a><\/p>\n

Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial
\nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9037186\/pdf\/bjgpjul-2022-72-720-butler-fl-oa-p.pdf<\/a><\/p>\n

Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial
\nhttps:\/\/www.thelancet.com\/action\/showPdf?pii=S2213-2600%2822%2900163-1<\/a><\/p>\n

Mikania glomerata Spreng. (Asteraceae): seu uso terap\u00eautico e seu potencial na Pandemia de COVID-19
\nhttps:\/\/revistafitos.far.fiocruz.br\/index.php\/revista-fitos\/article\/view\/1292\/1037<\/a><\/p>\n

mRNA-based COVID-19 Vaccines Booster Dose: Benefits, Risks and Coverage
\nhttps:\/\/www.mattioli1885journals.com\/index.php\/actabiomedica\/article\/view\/13103\/10836<\/a><\/p>\n

The Effect of Diabetes Mellitus on Mortality in Patients Hospitalized Intensive Care Unit in Covid-19 Pandemic
\nhttps:\/\/www.mattioli1885journals.com\/index.php\/actabiomedica\/article\/view\/11880\/10858<\/a><\/p>\n

Differences in saliva ACE2 activity among infected and non-infected adult and pediatric population exposed to SARS-CoV-2
\nhttps:\/\/www.journalofinfection.com\/action\/showPdf?pii=S0163-4453%2822%2900248-1<\/a><\/p>\n

Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol for outpatient treatment of mild coronavirus disease (COVID-19)
\nhttps:\/\/www.nature.com\/articles\/s41598-022-13920-9<\/a><\/p>\n

Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety (CANVAS) network cohort study
\nhttps:\/\/www.thelancet.com\/journals\/laninf\/article\/PIIS1473-3099(22)00426-1\/fulltext<\/a><\/p>\n

Reactivaci\u00f3n de glomerulonefritis l\u00fapica en asociaci\u00f3n temporal con vacunas anti sars-cov-2
\nhttps:\/\/www.medicinabuenosaires.com\/revistas\/vol82-22\/destacado\/casuistica_7802.pdf<\/a><\/p>\n

Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England: a population-based cohort study
\nhttps:\/\/www.thelancet.com\/action\/showPdf?pii=S2213-8587%2822%2900158-9<\/a><\/p>\n

Protection vaccinale et immunit\u00e9 \u00ab naturelle \u00bb face \u00e0 la COVID-19 : \u00e9quivalence ?
\nhttp:\/\/www.minerva-ebm.be\/FR\/GetPdf\/2306?articleId=2262<\/a><\/p>\n

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases
\nhttps:\/\/onlinelibrary.wiley.com\/doi\/epdf\/10.1111\/bjd.19163<\/a><\/p>\n

Frequency of Neurological Diseases After COVID-19, Influenza A\/B and Bacterial Pneumonia
\nhttps:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.904796\/full<\/a><\/p>\n

Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial<\/p>\n

https:\/\/www.thelancet.com\/action\/showPdf?pii=S2213-2600%2822%2900186-2<\/a><\/p>\n

Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people
\nhttps:\/\/www.thelancet.com\/pdfs\/journals\/laninf\/PIIS1473-3099(22)00427-3.pdf<\/a><\/p>\n

Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA1273
\nhttps:\/\/www.cell.com\/cell-reports-medicine\/pdf\/S2666-3791(22)00248-8.pdf<\/a><\/p>\n

Drug treatments for covid-19: living systematic review and network meta-analysis
\nhttps:\/\/www.bmj.com\/content\/370\/bmj.m2980#:~:text=Conclusions,patients%20with%20severe%20covid%2D19<\/a>.<\/p>\n

Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in Argentina: A retrospective cohort study
\nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9288143\/pdf\/main.pdf<\/a><\/p>\n

Autoimmune hepatitis and COVID-19: No increased risk for AIH after vaccination but reduced care
\nhttps:\/\/www.journal-of-hepatology.eu\/action\/showPdf?pii=S0168-8278%2822%2900120-9<\/a><\/p>\n

Autoimmune hepatitis (AIH) following coronavirus (COVID-19) vaccine \u2013 no longer exclusive to mRNA vaccine?
\nhttps:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/liv.15350<\/a><\/p>\n

Virologic and Immunologic Characterization of COVID-19 Recrudescence after Nirmatrelvir\/Ritonavir Treatment
\nhttps:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciac496\/6611663?login=false<\/a><\/p>\n

Association of COVID-19 Vaccination During Pregnancy With Incidence of SARS-CoV-2 Infection in Infants
\nhttps:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2793109<\/a><\/p>\n

Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial
\nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8757475\/pdf\/KGMI_14_2018899.pdf<\/a><\/p>\n

Analysis of Myocarditis Among 252 Million mRNA-1273 Recipients Worldwide
\nhttps:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciac446\/6603291?login=false<\/a><\/p>\n

Application of normative documents for determination of biocidal activity of disinfectants and antiseptics dedicated to the medical area: a narrative review
\nhttps:\/\/www.journalofhospitalinfection.com\/action\/showPdf?pii=S0195-6701%2822%2900108-6<\/a><\/p>\n

Frequency of Neurological Diseases After COVID-19, Influenza A\/B and Bacterial Pneumonia
\nhttps:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.904796\/full<\/a><\/p>\n

Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial
\nhttps:\/\/www.medrxiv.org\/content\/10.1101\/2022.06.10.22276252v1<\/a><\/p>\n

Lesiones faciales de vit\u00edligo tras la administraci\u00f3n de la vacuna frente a SARS-CoV-2
\nhttps:\/\/www.actasdermo.org\/es-pdf-S0001731022001600<\/a><\/p>\n

Uso de ciclosporina en dermatolog\u00eda durante la pandemia de COVID-19
\nhttps:\/\/www.actasdermo.org\/es-pdf-S0001731022004124<\/a><\/p>\n

Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2201300?articleTools=true<\/a><\/p>\n

Risk factors for SARS-CoV-2 infection and transmission in households with asthmatic and allergic children. A prospective surveillance study
\nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9155183\/<\/a><\/p>\n

Targeting SARS-CoV-2: An overview of COVID-19 treatments
\nhttps:\/\/www.medsafe.govt.nz\/profs\/PUArticles\/June2022\/Targeting-SARs-CoV-2-Overview-COVID-19-treatments.html<\/a><\/p>\n

Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine
\nhttps:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2792068<\/a><\/p>\n

Severe acute hepatitis in children: investigate SARS-CoV-2 superantigens
\nhttps:\/\/www.thelancet.com\/action\/showPdf?pii=S2468-1253%2822%2900166-2<\/a><\/p>\n

Famotidine activates the vagus nerve inflammatory reflex to attenuate cytokine storm
\nhttps:\/\/molmed.biomedcentral.com\/track\/pdf\/10.1186\/s10020-022-00483-8.pdf<\/a><\/p>\n

Advances in respiratory protective equipment: practical experiences of CleanSpace\u00ae HALO\u2122 by healthcare workers
\nhttps:\/\/www.journalofhospitalinfection.com\/article\/S0195-6701(22)00078-0\/fulltext#relatedArticles<\/a><\/p>\n

Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis
\nhttps:\/\/www.bmj.com\/content\/377\/bmj-2022-069989<\/a><\/p>\n

Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2118946<\/a><\/p>\n

Epidemiology of VITT (Vaccine-induced immune thrombotic thrombocytopenia)
\nhttps:\/\/www.sciencedirect.com\/science\/article\/pii\/S0037196322000051<\/a><\/p>\n

COVID-19 mRNA Vaccines Preserve Immunogenicity after Re-Freezing
\nhttps:\/\/www.mdpi.com\/2076-393X\/10\/4\/594<\/a><\/p>\n

Addition of a nutraceutical to montelukast or inhaled steroid in the treatment of wheezing during COVID-19 pandemic: a multicenter, open-label, randomized controlled trial
\nhttps:\/\/www.mattioli1885journals.com\/index.php\/actabiomedica\/article\/view\/11958\/10756<\/a><\/p>\n

Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance
\nhttps:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2792524<\/a><\/p>\n

Mortality in COVID-19 among women on hormone replacement therapy: a retrospective cohort study
\nhttps:\/\/academic.oup.com\/fampra\/advance-article\/doi\/10.1093\/fampra\/cmac041\/6585930?login=false<\/a><\/p>\n

Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study
\nhttps:\/\/journals.plos.org\/plosmedicine\/article\/authors?id=10.1371\/journal.pmed.1003991<\/a><\/p>\n

Effect of polymerised type I collagen on hyperinflammation of adult outpatients with symptomatic COVID-19
\nhttps:\/\/onlinelibrary.wiley.com\/doi\/epdf\/10.1002\/ctm2.763<\/a><\/p>\n

BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2205011<\/a><\/p>\n

Cetylpyridinium Chloride Mouthwash to Reduce Shedding of Infectious SARS-CoV-2: A Double-Blind Randomized Clinical Trial
\nhttps:\/\/journals.sagepub.com\/doi\/10.1177\/00220345221102310<\/a><\/p>\n

Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5\u201311 years in Italy: a retrospective analysis of January\u2013April, 2022
\nhttps:\/\/www.thelancet.com\/action\/showPdf?pii=S0140-6736%2822%2901185-0<\/a><\/p>\n

Imbalance in baseline characteristics in molnupiravir trials
\nhttps:\/\/www.bmj.com\/content\/377\/bmj.o977<\/a><\/p>\n

Incidence of Guillain-Barr\u00e9 Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink
\nhttps:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2791533<\/a><\/p>\n

Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine
\nhttps:\/\/onlinelibrary.wiley.com\/doi\/epdf\/10.1002\/dmrr.3465<\/a><\/p>\n

Two new oral antivirals for covid-19: molnupiravir and nirmatrelvir plus ritonavir
\nhttps:\/\/dtb.bmj.com\/content\/dtb\/60\/5\/73.full.pdf<\/a><\/p>\n

Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis
\nhttps:\/\/www.bmj.com\/content\/bmj\/377\/bmj-2022-069989.full.pdf<\/a><\/p>\n

Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5\u201311 Years and Adolescents Aged 12\u201315 Years \u2014 PROTECT Cohort, July 2021\u2013February 2022
\nhttps:\/\/www.cdc.gov\/mmwr\/volumes\/71\/wr\/pdfs\/mm7111e1-H.pdf<\/a><\/p>\n

Effect of Early Treatment with Ivermectin among Patients with Covid-19
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2115869?articleTools=true<\/a><\/p>\n

Antibody durability at 1 year after Sputnik V vaccination
\nhttps:\/\/www.thelancet.com\/action\/showPdf?pii=S1473-3099%2822%2900176-1<\/a><\/p>\n

Does smoking have an impact on the immunological response to COVID-19 vaccines? Evidence from the VASCO study and need for further studies
\nhttps:\/\/www.sciencedirect.com\/science\/article\/pii\/S0033350621004741?via%3Dihub<\/a><\/p>\n

SARS-CoV-2 vaccine-associated-tinnitus: A review
\nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8788157\/pdf\/main.pdf<\/a><\/p>\n

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2201570?articleTools=true<\/a><\/p>\n

SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies
\nhttps:\/\/www.science.org\/doi\/epdf\/10.1126\/scitranslmed.abn8543<\/a><\/p>\n

Inhibition of Respiratory RNA Viruses by a Composition of Ionophoric Polyphenols with Metal Ions<\/p>\n

https:\/\/www.mdpi.com\/1424-8247\/15\/3\/377\/htm<\/a><\/p>\n

Effect of Early Treatment with Ivermectin among Patients with Covid-19
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2115869?articleTools=true<\/a><\/p>\n

Risks and burdens of incident diabetes in long COVID: a cohort study
\nhttps:\/\/www.sciencedirect.com\/science\/article\/pii\/S2213858722000444<\/a><\/p>\n

Persistent COVID-19 Infection in Wiskott-Aldrich Syndrome Cleared Following Therapeutic Vaccination: a Case Report
\nhttps:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-021-01158-5.pdf<\/a><\/p>\n

Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities
\nThe I-TECH Randomized Clinical Trial
\nhttps:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2789362<\/a><\/p>\n

The presence of serum anti-SARS-CoV-2 IgA appears to protect primary health care workers from COVID-19
\nhttps:\/\/onlinelibrary.wiley.com\/doi\/epdf\/10.1002\/eji.202149655<\/a><\/p>\n

Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir
\nhttps:\/\/www.dovepress.com\/getfile.php?fileID=79350<\/a><\/p>\n

COVID-19-Associated Croup in Children
\nhttps:\/\/publications.aap.org\/pediatrics\/article\/doi\/10.1542\/peds.2022-056492\/185378\/COVID-19-Associated-Croup-in-Children<\/a><\/p>\n

Autoimmune hepatitis and COVID-19: No increased risk for AIH after vaccination but reduced care
\nhttps:\/\/www.journal-of-hepatology.eu\/action\/showPdf?pii=S0168-8278%2822%2900120-9<\/a><\/p>\n

SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis
\nhttps:\/\/www.journal-of-hepatology.eu\/article\/S0168-8278(22)00234-3\/pdf<\/a><\/p>\n

BNT162b2 Protection against the Omicron Variant in Children and Adolescents
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2202826?articleTools=true<\/a><\/p>\n

Management of Drug Interactions With Nirmatrelvir\/Ritonavir (Paxlovid\u00ae): Resource for Clinicians
\nhttps:\/\/www.idsociety.org\/globalassets\/idsa\/practice-guidelines\/covid-19\/treatment\/idsa-paxlovid-drug-interactions-resource-5-6-22-v1.1.pdf<\/a><\/p>\n

Durability of SARS-CoV-2 Antibodies From Natural Infection in Children and Adolescents
\nhttps:\/\/publications.aap.org\/pediatrics\/article\/doi\/10.1542\/peds.2021-055505\/185412\/Durability-of-SARS-CoV-2-Antibodies-From-Natural<\/a><\/p>\n

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2200674?articleTools=true<\/a><\/p>\n

Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2118691?articleTools=true<\/a><\/p>\n

Ministerio de Salud: Recomendaciones<\/strong><\/h2>\n